Ronas Shakya

Ronas Shakya

Auto-generated profile, based on publicly available information

Ronas Shakya

Centre for the Science of Learning & Technology (SLATE Univeristy of Bergen Bergen Norway

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


11 August 2021 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
AGAbhishek Giri
Abhishek Giri
AKAbhilasha Karkey
Abhilasha Karkey
SDSabina Dongol
Sabina Dongol
AAAmit Arjyal
Amit Arjyal
AMArchana Maharjan
Archana Maharjan
BBBuddha Basnyat
Buddha Basnyat
Background: Typhoid and paratyphoid fever (enteric fever) is a common cause of non-specific febrile infection in adults and children presenting to health care facilities in low resource settings such as the South Asia. A 7-day course of a single oral antimicrobial such as ciprofloxacin, cefixime or azithromycin is commonly used for its treatment. Increasing antimicrobial resistance threatens the effectiveness of these treatment choices. We hypothesize that combined treatment with azithromycin (active mainly intracellularly) and cefixime (active mainly extracellularly) will be a better option for the treatment of typhoid fever in South Asia. Methods: This is a phase IV, international multi-centre, multi-country, comparative participant-and observer-blind, 1:1 randomised clinical trial. Patients with suspected uncomplicated typhoid fever will be randomised to one of the two interventions: Arm A: azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) and cefixime 20mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days, Arm B: azithromycin 20mg/kg/day oral dose once daily (max 1gm/day) for 7 days AND cefixime-matched placebo for 7 days. We will recruit 1500 patients across sites in Bangladesh, India, Nepal and Pakistan. We will assess whether treatment outcomes are better with the combination after one week of treatment and at one- and three-months follow-up. Discussion: Combined treatment may limit the emergence of resistance if one of the components is active against resistant sub-populations not covered by the other antimicrobial’s activity. If the combined treatment is better than the single antimicrobial treatment, this will be an important result for patients across South Asia and other typhoid endemic areas. Clinicaltrials.gov registration: NCT04349826 (16/04/2020)

12 November 2021 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
AGAbhishek Giri
Abhishek Giri
AKAbhilasha Karkey
Abhilasha Karkey
SDSabina Dongol
Sabina Dongol
AAAmit Arjyal
Amit Arjyal
AMArchana Maharjan
Archana Maharjan
BBBuddha Basnyat
Buddha Basnyat
Background: Typhoid and paratyphoid fever (enteric fever) is a common cause of non-specific febrile infection in adults and children presenting to health care facilities in low resource settings such as the South Asia. A 7-day course of a single oral antimicrobial such as ciprofloxacin, cefixime, or azithromycin is commonly used for its treatment. Increasing antimicrobial resistance threatens the effectiveness of these treatment choices. We hypothesize that combined treatment with azithromycin (active mainly intracellularly) and cefixime (active mainly extracellularly) will be a better option for the treatment of clinically suspected and culture-confirmed typhoid fever in South Asia. Methods: This is a phase IV, international multi-center, multi-country, comparative participant-and observer-blind, 1:1 randomised clinical trial. Patients with suspected uncomplicated typhoid fever will be randomized to one of the two interventions: Arm A: azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) and cefixime 20mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days, Arm B: azithromycin 20mg/kg/day oral dose once daily (max 1gm/day) for 7 days AND cefixime-matched placebo for 7 days. We will recruit 1500 patients across sites in Bangladesh, India, Nepal, and Pakistan. We will assess whether treatment outcomes are better with the combination after one week of treatment and at one- and three-months follow-up. Discussion: Combined treatment may limit the emergence of resistance if one of the components is active against resistant sub-populations not covered by the other antimicrobial activity. If the combined treatment is better than the single antimicrobial treatment, this will be an important result for patients across South Asia and other typhoid endemic areas. Clinicaltrials.gov registration: NCT04349826 (16/04/2020)


16 March 2025 in arXiv
Verified
Preprint
Open access
PDF file
RSRonas Shakya
Ronas Shakya
FVFarhad Vadiee
Farhad Vadiee
Mohammad KhalilMohammad Khalil
Mohammad Khalil
The advancement of large language models (LLMs) has created a competitive landscape for AI-assisted programming tools. This study evaluates two leading models: ChatGPT 03-mini and DeepSeek-R1 on their ability to solve competitive programming tasks from Codeforces. Using 29 programming tasks of three levels of easy, medium, and hard difficulty, we assessed the outcome of both models by their accepted solutions, memory efficiency, and runtime performance. Our results indicate that while both models perform similarly on easy tasks, ChatGPT outperforms DeepSeek-R1 on medium-difficulty tasks, achieving a 54.5% success rate compared to DeepSeek 18.1%. Both models struggled with hard tasks, thus highlighting some ongoing challenges LLMs face in handling highly complex programming problems. These findings highlight key differences in both model capabilities and their computational power, offering valuable insights for developers and researchers working to advance AI-driven programming tools.